ClinAssess GmbH
23
0
2
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
13.0%
3 terminated/withdrawn out of 23 trials
76.9%
-9.6% vs industry average
17%
4 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (23)
Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia
Role: collaborator
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
Role: collaborator
Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q
Role: collaborator
Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer
Role: collaborator
Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer
Role: collaborator
FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)
Role: collaborator
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
Role: collaborator
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Role: collaborator
Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma
Role: collaborator
First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine
Role: collaborator
Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
Role: collaborator
Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
Role: collaborator
A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)
Role: collaborator
Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL
Role: collaborator
PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood
Role: collaborator
A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma
Role: collaborator
SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment
Role: collaborator
Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer
Role: collaborator
CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer
Role: collaborator
A Phase II Trial on Treatment of Steroid-refractory Bronchiolitis Obliterans With Interferon Gamma 1b After Allogeneic SCT
Role: collaborator